Foveal vision is impaired in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 1, 2013, Pages 1-14

  Bodis Wollner, Ivan ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

Contrast sensitivity; Dopamine; ERG VEP; Fovea; Higher visual dysfunction; Isoluminance colour contrast; Optical coherence tomography (OCT); PERG; Retina; Visual cortex

Indexed keywords

ANATOMICAL CONCEPTS; CELL DENSITY; COLOR VISION; CONTRAST SENSITIVITY; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA FOVEA; RETINA GANGLION CELL; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; STRIATE CORTEX; VISUAL ACUITY; VISUAL CORTEX; VISUAL DISCRIMINATION; VISUAL FIELD; VISUAL IMPAIRMENT; VISUAL INFORMATION; VISUAL SYSTEM FUNCTION;

FOVEA CENTRALIS; HUMANS; MALE; NERVE FIBERS; PARKINSON DISEASE; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VISION, OCULAR;

EID: 84871513769     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.07.012     Document Type: Review

References (157)

1. Bodis-Wollner I., Onofrj M. The visual system in Parkinson's disease. Advances in neurology 1986, vol. 45:323-327. Raven Press, New York.
2. Bodis-Wollner I. Visual deficit related to dopamine deficiency in experimental animals and Parkinson's disease. Trends Neurosci 1990, 13:296-301.
3. Witkowsky P. Dopamine and retinal function. Doc Ophthalmol 2000, 108:17-41.
4. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. The retina in Parkinson's disease. Brain 2009 May, 132(Pt 5):1128-1145.
5. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009 Nov, 116(11):1493-1501.
6. Rolls E.T., Cowey A. Topography of the retina and striate cortex and its relationship to visual acuity in rhesus monkeys and squirrel monkeys. Exp Brain Res 1970, 10:298-310.
7. Cowey A., Rolls E.T. Human cortical magnification factor and its relation to visual acuity. Exp Brain Res 1975, 21:447-454.
8. Drasdo N. The neural representation of visual space. Nature 1977 Apr 7, 266(5602):554-556.
9. Campbell F.W., Green D.C. Optical and retinal factors affecting visual resolution. J Physiol 1965, 181:576-593.
10. Owsley C., Sloane M.E. Contrast sensitivity, acuity, and the perception of 'real-world' targets. Br J Ophthalmol 1987, 71(10):791-796.
11. Huang D., Swanson E.A., Lin C.P., Schuman J.S., Stinson W.G., Chang W., et al. Optical coherence tomography. Science 1991, 254(5035):1178-1181.
12. Wojtkowski M., Srinivasan V., Fujimoto J.G., Ko T., Schuman J.S., Kowalczyk A., et al. Three-dimensional retinal imaging with high speed ultrahigh resolution optical coherence tomography. Ophthalmology 2005, 112:1734-1746.
13. Drasdo N., Thompson D.A., Arden G. A comparison of pattern electroretinogram amplitudes and nuclear layer thickness in different zones of the retina. Clin Vis Sci 1990, 5(4):415-420.
14. Marmor M.F., Hood D.C., Keating D., Kondo M., Mathias W., Seeliger M.W., et al. Guidelines for basic multifocal electroretinography (mfERG). Doc Ophthalmol 2003, 106:105-115.
15. Pelli D. Uncertainty explains many aspects of visual contrast detection and discrimination. J Opt Soc Am 1985, 9:1508-1532.
16. Paulus W.M., Straube A., Brandt T. Visual stabilization of posture. Physiological stimulus characteristics and clinical aspects. Brain 1984 Dec, 107(Pt 4):1143-1163.
17. Brown L.A., Cooper S.A., Doan J.B., Dickin D.C., Whilshaw I.Q., Pellis S.M. Impaired foveal processing and cognitive visual deficits in PD warrant further studies. Parkinsonism Relat Disord 2006 Sep, 12(6):376-381.
18. Adamovich S.V., Berkinblit M.B., Hening W., Sage J., Poizner H. The interaction of visual and proprioceptive inputs in pointing to actual and remembered targets in Parkinson's disease. Neuroscience 2001, 104(4):1027-1041.
19. Owen A.M., Beksinska M., James M., Leigh P.N., Summers B.A., Marsden C.D., et al. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 1993 Jul, 31(7):627-644.
20. Suarez H., Geisinger D., Suarez A., Carrera X., Buzo R., Amorin I. Postural control and sensory perception in patients with Parkinson's disease. Acta Otolaryngol 2008, 19:1-7.
21. Rolls E.T. Top-down control of visual perception: attention in natural vision. Perception 2008, 37:333-354.
22. Retina 2006, 888-889. MOSBY, St. Louis. 4th ed. S.J. Ryan (Ed.).
23. Cline D., John R., Griffin J.R., Henry W., Hofstetter H.W. Dictionary of visual science 2000, Butterworth-Heinemann, London. 5th ed.
24. Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. Science 1972, 178:769-771.
25. Bodis-Wollner I., Diamond S. The measurement of spatial contrast sensitivity in cases of blurred vision associated with cerebral lesions. Brain 1976, 99:695-710.
26. Bodis-Wollner I., Marx M.S., Mitra S., Bobak P., Mylin L., Yahr M. Visual dysfunction in Parkinson's disease. Brain 1987, 110:1675-1698.
27. Kuffler S.W. Discharge patterns and functional organization of mammalian retina. J Neurophysiol 1953, 1:37-68.
28. Enroth-Cugell C., Robson J.G. The contrast sensitivity of retinal ganglion cells of the cat. J Physiol 1966, 187(3):517-552.
29. Bodis-Wollner I., Bender M.B. Neuro-ophthalmology: electrophysiology and psychophysics of acuity and contrast detection. Prog Neurol Psychiatry 1973, vol. 28:93-115.
30. Bodis-Wollner I., Yahr M.D. Measurement of visual evoked potentials in Parkinson's disease. Brain 1978, 101:661-671.
31. Drasdo N. Cortical potentials evoked by pattern presentation in the foveal region. Evoked potentials 1980, MTP Press, Lancaster. C. Barber (Ed.).
32. Bodis-Wollner I. The significance of the foveal pattern VEP. Evoked potentials III 1987, 31-39. Butterworths, Boston. C. Barber, T. Blum (Eds.).
33. Tartaglione A., Pizio N., Bino G., Spadavecchia L., Favale E. VEP changes in Parkinson's disease are stimulus dependent. J Neurol Neurosurg Psychiatr 1984 Mar, 47(3):305-307.
34. Nightingale S., Mitchell K.W., Howe J.W. Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. J Neurol Neurosurg Psychiatr 1986 Nov, 49(11):1280-1287.
35. Bodis-Wollner I., Yahr M.D., Thornton J. Visual evoked potentials and the severity of Parkinson's disease. Research progress in Parkinson's disease 1981, 126-137. Pitman Medical, Tunbridge Wells. C. Rose, R. Capildeo (Eds.).
36. Dowling J.E., Ehinger B. Synaptic organization of the amine-containing interplexiform cells of the goldfish and Cebus monkey retinas. Science 1975 Apr 18, 188(4185):270-273.
37. Frederick J.M., Rayborn M.E., Laties A.M., Lam D.M., Hollyfield J.G. Dopaminergic neurons in the human retina. J Comp Neurol 1982, 210(1):65-79.
38. Bodis-Wollner I., Yahr M.D., Mylin L.H., Thornton J. Dopaminergic deficiency and delayed visual evoked potentials in humans. Ann Neurol 1982, ll:478-483.
39. Onofrj M., Ghilardi M.F., Basciani M., Gambi D. Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J Neurol Neurosurg Psychiatr 1986, 49(10):1150-1159.
40. Stanzione P., Fattapposta F., Tagliati M., D'Alessio C., Marciani M.G., Foti A., et al. Dopaminergic pharmacological manipulations in normal humans confirm the specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological alterations in Parkinson's disease. Electroencephalogr Clin Neurophysiol Suppl 1990, 41:216-220.
41. Bhaskar P.A., Vanchilingam S., Bhaskar E.A., Devaprabhu A., Ganesan R.A. Effect of L-dopa on visual evoked potential in patients with Parkinson's disease. Neurology 1986, 36:1119-1121.
42. Domenici L., Trimarchi C., Piccolino M., Fiorentini A., Maffei L. Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol 1985, 4(3):195-197.
43. Bartel P., Blom M., Robinson E., Meyden C., Sommers K., Becker P. The effects of levodopa and haloperidol on flash and pattern ERG-s and VEPs in normal humans. Doc Ophthalmol 1990, 76:55-64.
44. Masson G., Mestre D., Blin O. Dopaminergic modulation of visual sensitivity in man. Fundam Clin Pharmacol 1993, 7(8):449-463.
45. Hutton J.T., Morris J.L., Elias J.W. Levodopa improves spatial contrast sensitivity in Parkinson's disease. Arch Neurol 1993, 50:721-724.
46. Peppe A., Stanzione P., Pierelli F., De Angelis D., Pierantozzi M., Bernardi G. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology 1995 Jun, 45(6):1144-1148.
47. Stanzione P., Pierantozzi M., Semprini R., Tagliati M., Traversa R., Peppe A., et al. Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram. Vis Res 1995 Sep, 35(18):2659-2664.
48. Peppe A., Stanzione P., Pierantozzi M., Semprini R., Bassi A., Santilli A.M., et al. Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?. Electroencephalogr Clin Neurophysiol 1998, 106(4):374-382.
49. Bodis-Wollner I., Camisa J. Contrast sensitivity measurement in clinical diagnosis. Neuro-ophthalmology 1980, vol. I:373-401. Excerpta Medica, Amsterdam.
50. Regan D., Neima D. Low-contrast letter charts in early diabetic retinopathy, ocular hypertension, glaucoma, and Parkinson's disease. Br J Ophthalmol 1984, 68(12):885-889.
51. Bulens C., Meerwaldt J.D., van der Wildt G.J., Keemink C.J. Contrast sensitivity in Parkinson's disease. Neurology 1986, 36:1121-1125.
52. Watson A.B., Barlow H.B., Robson J.G. What does the eye see best?. Nature 1983, 302(5907):419-422.
53. Toner C.K., Reese B.E., Neargarder S., Riedel T.M., Gilmore G.C., Cronin-Golomb A. Vision-fair neuropsychological assessment in normal aging, Parkinson's disease and Alzheimer's disease. Psychol Aging 2011 Dec 26, [Epub ahead of print].
54. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Mov Disord 2011 Nov, 26(13):2387-2395. [Epub 2011 Sep 27]. 10.1002/mds.23891.
55. Bodis-Wollner I., Harnois C., Bobak P., Mylin L.H. On the possible role of temporal delays of afferent processing in Parkinson's disease. J Neural Transm Suppl 1983, 19:243-252.
56. Marx M., Bodis-Wollner I., Bobak P., Harnois C., Mylin M. Temporal frequency-dependent VEP changes in Parkinson's disease. Vis Res 1986, 26:185-193.
57. Maffei L., Fiorentini A., Bisti S., Hollander H. Pattern ERG in the monkey after section of the optic nerve. Exp Brain Res 1985, 59:423-425.
58. Hood D.C., Greenstein V., Frishman L., Holopigian K., Viswanathan S., Seiple W., et al. Identifying inner retinal contributions to the human multifocal ERG. Vis Res 1999 Jun, 39(13):2285-2291.
59. Tagliati M., Bodis-Wollner I., Kovanecz I., Stanzione P. Spatial frequency tuning of the monkey pattern ERG depends on D2 receptor-linked action of dopamine. Vis Res 1994, 34:2051-2057.
60. Gottlob I., Schneider E., Heider W., Skrandies W. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1987, 66(4):349-357.
61. Calzetti S., Franchi A., Taratufolo G., Groppi E. Simultaneous VEP and PERG investigations in early Parkinson's disease. J Neurol Neurosurg Psychiatr 1990 Feb, 53(2):114-117.
62. Stanzione P., Traversa R., Pierantozzi M., Semprini R., Marciani M.G., Bernardi G. An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease. Neurosci Lett 1992 Jun 8, 140(1):125-128.
63. Peppe A., Stanzione P., Pierelli F., Stefano E., Rizzo P.A., Tagliati M., et al. Low contrast stimuli enhance PERG sensitivity to the visual dysfunction in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1992 Jun, 82(6):453-457.
64. Ikeda H., Head G.M., Ellis C.J. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study. Vis Res 1994, 34:2629-2638.
65. Tagliati M., Bodis-Wollner I., Yahr M. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol 1995, 100:1-11.
66. Sartucci F., Orlandi G., Lucetti C., Bonuccelli U., Murri L., Orsini C., et al. Changes in pattern electroretinograms to equiluminant red-green and blue-yellow gratings in patients with early Parkinson's disease. J Clin Neurophysiol 2003, 20(5):375-381.
67. Sartucci F., Orlandi G., Bonuccelli U., Borghetti D., Murri L., Orsini C., et al. Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease. Neurol Sci 2006 Feb, 26(6):395-401.
68. Moschos M.M., Tagaris G., Markopoulos I., Margetis I., Tsapakis S., Kanakis M, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol 2011, 21(1):24-29.
69. Palmowski-Wolfe A.M., Perez M.T., Behnke S., Martziniak M., Ruprecht K.W. Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG. Doc Ophthalmol 2006, 112:209-215.
70. Ghilardi M.F., Bodis-Wollner I., Onofrj M.C., Marx M.S., Glover A.A. Spatial frequency dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 1988, 3:131-184.
71. Ghilardi M.F., Marx M.S., Bodis-Wollner I., Camras C.B., Glover A.A. The effect of intraocular 6-hydroxydopamine on retinal processing of primates. Ann Neurol 1989, 25:357-364.
72. Peppe A., Antal A., Tagliati M., Stanzione P., Bodis-Wollner I. Dl agonist CY208-243 attenuates the PERG to low spatial frequency stimuli in the monkey. Neurosci Lett 1998, 242:1-4.
73. Bodis-Wollner I., Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vis Res 1998, 38:1479-1487.
74. Bodis-Wollner I., Tzelepi A. Push-pull model of dopamine's action in the retina. Models of the visual system 2002, 191-214. Kluwer Academic/Plenum Publishers, New York, Boston, Dordrecht, London and Moscow, [Chapter 5]. G.K. Hung, K.J. Ciuffreda (Eds.).
75. Sutter E. Noninvasive testing methods: multifocal electrophysiology. Encyclopedia of the eye 2010, vol. 3:142-160. Academic Press, Oxford.
76. Birch J., Kolle R.U., Kunkel M., Paulus W., Upadhyay P. Acquired colour deficiency in patients with Parkinson's disease. Vis Res 1988, 38:3421-3426.
77. Price M., Feldman R., Adelberg D., Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992, 42:887-890.
78. Haug B.A., Trenkwalder C., Arden G.B., Oertel W.H., Paulus W. Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease. Mov Disord 1994 Sep, 9(5):563-570.
79. Pieri V., Diederich N.J., Raman R., Goetz C.G. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000, 172(1):7-11.
80. Büttner T., Kuhn W., Müller T., Heinze T., Pühl C., Przuntek H. Chromatic and achromatic visual evoked potentials in Parkinson's disease. Electroencephalogr Clin Neurophysiol 1996 Sep, 100(5):443-447.
81. Sartucci F., Porciatti V. Visual-evoked potentials to onset of chromatic red-green and blue-yellow gratings in Parkinson's disease never treated with L-dopa. J Clin Neurophysiol 2006 Oct, 23(5):431-451.
82. Silva M.F., Faria P., Regateiro F.S., Forjaz V., Januário C., Freire A., et al. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain 2005, 10:2260-2271.
83. Regan D., Maxner C. Orientation-selective visual loss in patients with Parkinson's disease. Brain 1987 Apr, 110(Pt 2):415-432.
84. Trick G., Kaskie B., Steinman S. Visual impairment in Parkinson's disease in orientation and motion discrimination. Optom Vis Sci 1994, 71:242-245.
85. Watson G., Keltner J., Chin E., Harvey D., Nguyen A., Park S.S. Comparison of retinal nerve fiber layer and central macular thickness measurements among five different optical coherence tomography instruments in patients with multiple sclerosis and optic neuritis. J Neuroophthalmol 2011, 31(2):110-116.
86. Sull A., Vuong L., Price L., Srinivasan V., Gorczynska I., Fujimoto J., et al. Comparison of spectral/fourier domain optical coherence tomography instruments for assessment of normal macular thickness. Retina 2010, 30:235-245.
87. Tatrai E., Ranganathan S., Ferencz M., DeBuc D.C., Somfai G.M. Comparison of retinal thickness by Fourier-domain optical coherence tomography and OCT retinal image analysis software segmentation analysis derived from Stratus optical coherence tomography images. J Biomed Opt May 2011, 16(5):056004.
88. Provis J.M., Hendrickson A.E. The foveal avascular region of developing human retina. Arch Ophthalmol 2008, 126:507-511.
89. Inzelberg R., Ramirez J.A., Nisipeanu P., Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vis Res 2004, 44:2793-2797.
90. Altintas O., Iseri P., Ozkan B., Caglar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinsons disease. Doc Ophthalmol 2008, 1116:137-146.
91. Hajee M., March W., Lazzaro D., Wolintz A., Shrier E., Glazman S., et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009, 127(6):737-741.
92. Aaker G.D., Myung J.S., Ehrlich J.R., Mohammed M., Henchcliffe C., Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol 2010, 4:1427-1432.
93. Cubo E., Mendez V.R., Galan J.M.T.G. Retina thickness in Parkinson's disease and essential tremor. Mov Disord 2010, 25:2461-2477.
94. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011 Jul, 17(6):431-436. [Epub 2011 Mar 31].
95. La Morgia C., Carbonelli M., Barboni P., et al. Age-related temporal loss of retinal nerve fibers in Parkinson disease: a mitochondrial pattern?. Invest Ophthalmol Vis Sci 2011, 52(E-A):2984-2994.
96. Bodis-Wollner I., Spund B., Liu T., Shrier E., Selesnick I., Glazman S., et al. Remodeling of the fovea in Parkinson disease. Invest Ophthalmol Vis Sci 2011, 52. [E-Abstract 6660].
97. Wong A.C., Chan C.W., Hui S.P. Relationship of gender, body mass index, and axial length with central retinal thickness using optical coherence tomography. Eye 2005, 19:292-297.
98. Asefzadeh B., Cavallerano A.A., Fisch B.M. Racial differences in macular thickness in healthy eyes. Optom Vis Sci 2007, 84:E941-E945.
99. Kelty P.J., Payne J.F., Trivedi R.H., Kelty J., Bowie E.M., Burger B.M. Macular thickness assessment in healthy eyes based on ethnicity using Stratus OCT optical coherence tomography. Invest Ophthalmol Vis Sci 2008, 49:2668-2672.
100. Kashani A.H., Zimmer-Galler E.S., Shah S.M., Dustin L., Do D.V., Eliott D., et al. Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol 2010, 149:496-502.
101. Grover S., Murthy R.K., Brar V.S., Chalam K.V. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 2009, 148:266-271.
102. Wagner-Schuman M., Dubis A., Nordgren R., Lei Yodell D., Chiao H., Weh E., et al. Race- and sex-related differences in retinal thickness and foveal pit morphology. Invest Ophthalmol Vis Sci 2011, 52:625-634.
103. Göbel W., Hartmann F., Haigis W. Determination of retinal thickness in relation to the age and axial length using optical coherence tomography. Ophthalmologe 2001 Feb, 98(2):157-162.
104. Song W.K., Lee S.C., Lee E.S., Kim C.Y., Kim S.S. Macular thickness variations with sex, age, and axial length in healthy subjects: a spectral domain-optical coherence tomography study. Invest Ophthalmol Vis Sci 2010, 51:3913-3918.
105. Sull A.C., Vuong L.N., Price L.L., Srinivasan V.J., Gorczynska I., Fujimoto J.G., et al. Comparison of spectral/Fourier domain optical coherence tomography instruments for assessment of normal macular thickness. Retina 2010 Feb, 30:235-245.
106. Ooto S., Hangai M., Sakamoto A., Tomidokoro A., Araie M., Otani T., et al. Three-dimensional profile of macular retinal thickness in normal Japanese eyes. Invest Ophthalmol Vis Sci 2010, 51:465-473.
107. Bagci A.M., Shahidi M., Ansari R., Blair M., Blair N.P., Zelkha R. Thickness profiles of retinal layers by optical coherence tomography image segmentation. Am J Ophthalmol 2008 Nov, 146(5):679-687. [Epub 2008 Aug 15].
108. Loduca A., Zhang C., Zelkha R., Shahidi Thickness mapping of retinal layers by spectral-domain optical coherence tomography. Am J Ophthalmol 2010, 149:849-853.
109. Yang Q., Reisman C.A., Wang Z., Fukuma Y., Hangai M., Yoshimura N. Automated layer segmentation of macular OCT images using dual-scale gradient information. Opt Express 2010 Sep 27, 18(20):21293-21307. 10.1364/OE.18.021293.
110. Hood D.C., Cho J., Raza A.S., Dale E.A., Wang M. Reliability of a computer-aided manual procedure for segmenting optical coherence tomography scans. Optom Vis Sci 2011 Jan, 88(1):113-123.
111. Bayer A.U., Keller O.N., Ferrari F., Maag K.P. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 2002 Jan, 133(1):135-137.
112. Rudnicka A.R., Mt-Isa S., Owen C.G., Cook D.G., Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci October 2006, 47(10):4254-4261.
113. El-Ashry M., Hegde V., James P., Pagliarini S. Analysis of macular thickness in British population using optical coherence tomography (OCT): an emphasis on interocular symmetry. Curr Eye Res 2008, 33:693-699.
114. Tick S., Rossant F., Ghorbei I., Gaudric A., Sahel J.-A., Chaumet-Riffaud P., et al. Foveal shape and structure in a normal population. Invest Ophthalmol Vis Sci 2011 Jul 29, 52(8):5105-5110. [Print 2011 Jul].
115. Yavas G.F., Yilmaz O., Küsbeci T., Oztürk F. The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 2007, 17:812-816.
116. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 1988, 10(2):137-144.
117. Djamgoz M.B., Hankins M.W., Hirano J., Archer S.N. Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vis Res 1997, 37:3509-3529.
118. Harnois C., Di Paolo T. Decreased dopamine in the retinas of patients with Parkinsons disease. Invest Ophthalmol Vis Sci 1990, 31:2473-2475.
119. Ghilardi M.F., Chung E., Bodis-Wollner I., Dvorzniak M., Glover A., Onofrj M. Systemic l-methyl, 4-phenyl, l-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 1988, 43:255-262.
120. Zhang D.-Q., Wong K.Y., Sollars P.J., Berson D.M., Pickard G.E., McMahon D.G. Intraretinal signaling by ganglion cell photoreceptors to dopaminergic amacrine neurons. Proc Natl Acad Sci U S A 2008 Sep 16, 105(37):14181-14186. [Epub 2008 Sep 8].
121. Piccolino M., Neyton J. The feedback effect from luminosity horizontal cells to cones in the turtle retina: a key to understanding the response properties of the horizontal cells. Prog Clin Biol Res 1982, 13:161-179. [Review].
122. Lasater E.M., Dowling J.E. Dopamine decreases conductance of the electrical junctions between cultured retinal horizontal cells. Proc Natl Acad Sci U S A 1985, 82:3025-3029.
123. Mangel S.C., Dowling J.E. Responsiveness and receptive field size of carp horizontal cells are reduced by prolonged darkness and dopamine. Science 1985, 229:1107-1109.
124. Piccolino M., Neyton J., Gerschenfeld H.M. Horizontal cells of turtle retina: a neurotransmitter control of electrical junctions?. J Physiol Paris 1982-1983, 78(8):739-742.
125. Piccolino M., Demontis G., Witkovsky P., Strettoi E., Cappagli G.C., Porceddu M.L., et al. Involvement of D1 and D2 dopamine receptors in the control of horizontal cell electrical coupling in the turtle retina. Eur J Neurosci 1989 May, 1(3):247-257.
126. Hampson E.C., Vaney D.I., Weiler R. Dopaminergic modulation of gap junction permeability between amacrine cells in mammalian retina. J Neurosci 1992, 12:4911-4922.
127. Nguyen-Legros J., Simon A., Caillé I., Bloch B. Immunocytochemical localization of dopamine D1 receptors in the retina of mammals. Vis Neurosci 1997, 14(3):545-551.
128. Nguyen-Legros J., Versaux-Botteri C., Vernier P. Dopamine receptor localization in the mammalian retina. Mol Neurobiol 1999, 19(3):181-204.
129. Bodis-Wollner I., Brannan J.R., Storch R.L., Hajee M., Minko The effect of background spatial contrast on electroretinographic responses in the human retina. Vision Res 2009, 49:922-930.
130. Delalande I., Hache J.C., Forzy G., Bughin M., Benhadjali J., Destée A. Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson's disease and multiple system atrophy?. Mov Disord 1998 May, 13(3):44.
131. Diederich N.J., Raman R., Leurgans S., Goetz C.G. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002, 59:1249-1252.
132. Uc E.Y., Rizzo M., Anderson S.W., Qian S.M.S., Rodnitzky R.L., Dawson J.D. Visual dysfunction in Parkinson disease without dementia. Neurology 2005, 65:1907-1913.
133. Lalezary M., Medeiros F.A., Weinreb R.N., Bowd C., Sample P.A., Tavares I.M., et al. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. Am J Ophthalmol 2006, 142:576-582.
134. Fisher J.B., Jacobs D.A., Markowitz C.E., Galetta S.L., Volpe N.J., Nano-Schiavi ML, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006, 113:324-332.
135. Blanks J.C.Y., Torigoe Y., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer's disease. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996, 17:377-384.
136. Berisha F., Feke G.T., Trempe C.L., McMeel J.W., Schepens C.L. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007, 48:2285-2289.
137. Guo L.J., Duggan J.M., Cordeiro F. Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 2010, 7:3-14.
138. Kesler A., Vakhapova V., Korczyn A.D., Naftaliev E., Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 2011, 13:5230-5238.
139. Braak H., Del Tredici K., Bratzke H., Hamm Clement J., Sandmann-Keil D., Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002, 249:1-5.
140. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
141. Braak H., de Vos R.A.I., Bohl J., Del Tredici K. Gastric alpha-synucleinoimmunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
142. Braak H., Sastre M., Bohl J.R.E., de Vos R.A.I., Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007, 113:421-429.
143. Ghebremedhin E., Del Tredici K., Langston J.W., Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009, 118:777-784.
144. Del Tredici K., Hawkes C.H., Ghebremedhin E., Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010, 121:703-713.
145. Martínez-Navarrete G.C., Martín-Nieto J., Esteve-Rudd J., Angulo A., Cuenca N. Alpha synuclein gene expression profile in the retina of vertebrates. Mol Vis 2007 Jun 18, 13:949-961.
146. Esteve-Rudd J., Campello L., Herrero M.T., Cuenca M., Martin-Nieto J. Expression in the mammalian retina of parkin and UCH-L1, two components of the ubiquitin-proteasome system. Brain Res 2010 Sep 17, 1352:70-82.
147. Goffaux V., van Zoon J., Schiltz C. The horizontal tuning of face perception relies on the processing of intermediate and high spatial frequencies. J Vis 2011 Sep 7, 11(10).
148. Reader T.A., Quesney L.F. Dopamine in the visual cortex of the cat. Experientia 1986, 42:1242-1244.
149. Phillipson O.T., Kilpatrick I.C., Jones M.W. Dopaminergic innervation of the primary visual cortex in the rat, and some correlations with the human cortex. Brain Res Bull 1987, 18:621-633.
150. Parkinson D. Evidence for a dopaminergic innervation of cat primary visual cortex. Neuroscience 1989, 30:171-179.
151. Rakic P., Lidow M. Distribution and density of monoamine receptors in the primate visual cortex devoid of retinal input from early embryonic stages. J Neurosci 1995, 15:2561-2574.
152. Bohnen N.I., Minoshima S., Giordani B., Frey K.A., Kuhl D.E. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999 Feb, 52(3):541-546.
153. De Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., et al. Prediction of cognitive decline in elderly subjects with 2-18F fluoro-2-deoxy-d-glucose/positron emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001, 98:10966-10971.
154. Antal A., Pfeiffer R., Bodis-Wollner I. Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease. J Neural Transm 1996, 103:1053-1067.
155. Sagliocco L., Bandini F., Pierantozzi M., Mari Z., Tzelepi A., Ko C., et al. Electrophysiological evidence for visuocognitive dysfunction in younger non-Caucasian patients with Parkinson's disease. J Neural Transm 1997, 104:427-439.
156. Antal A., Kéri S., Dibó G., Benedek G., Janka Z., Vécsei L., et al. Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease. Brain Res Cogn Brain Res 2002, 13(2):153-159.
157. Antal A., Kéri S., Kincses Z.T., Dibó G., Szabó A., Benedek G., et al. Dopaminergic contributions to the visual categorization of natural scenes: evidence from Parkinson's disease. J Neural Transm 2003 Jul, 110(7):757-770.